Trial Profile
Phase 2a, Multi-center, Placebo-controlled, Randomized, Partially Blinded, Study Infused TK112690 or or Placebo Administered Along With Methotrexate Weekly for Four Consecutive Weeks to Patients With Recurrent or Residual SCCHN
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Aug 2023
Price :
$35
*
At a glance
- Drugs TK 112690 (Primary) ; Methotrexate
- Indications Mucositis
- Focus Proof of concept; Therapeutic Use
- Sponsors Tosk
- 10 Jan 2020 Status changed from active, no longer recruiting to completed.
- 16 Oct 2019 Planned End Date changed from 15 Mar 2020 to 10 Mar 2020.
- 16 Oct 2019 Status changed from completed to active, no longer recruiting.